EN DE

LifeTech Scientific Corp (1302) Fair Value & Analysis

Healthcare · HK · Market cap HK$6.1B

LS LifeTech Scientific Corp 1302 · HK
PriceHK$1.40
Fair ValueHK$0.8600
Upside-38.6%
Quality68/100
Watch LifeTech Scientific Corp for free, get notified when fair value or trend changes. Watch for free
Healthy Growth
Solidly profitable · 10.8% net margin
Low debt · generates free cash flow
Mixed vs. peers (7/14)
Moderate moat 47/100
Evidence: High Range HK$0.6600 – HK$1.07 Share as image

Fair value as of: Aug 13, 2026

From 26 valuation models · updated 3 days ago

Share price −2.1% over the past month.

A solid business, but screening 39% overvalued on our models.

What matters now

  • The price sits above even our optimistic bull case (HK$1.07). The favourable scenario is already priced in.
  • Solid but not exceptional quality (68/100) and above fair value, neither a clear bargain nor a standout compounder.
Share this valuation: 𝕏 WhatsApp

Price vs Fair Value (5 years)

HK$5.62 HK$1.26 Fair Value HK$0.8600 Mar 2021 Aug 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 13, 2026.

How to read this chart

60‑month range HK$1.26 – HK$5.62 · fair‑value band HK$0.6600 – HK$1.07 · the HK$1.40 price screens above the HK$0.8600 fair value. Dashed = 300-day average. As of Aug 13, 2026.

Full chart & analysis →

Which stocks are undervalued right now? Check free Discover now →

Analysis

LifeTech Scientific Corp (1302) currently trades at HK$1.40, while our model-based Fair Value estimate is HK$0.8600, implying the stock looks roughly 38.6% overvalued today. The Quality Score stands at 68/100 (solid quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: high).

Over the trailing twelve months, LifeTech Scientific Corp generated revenue of HK$1.4B at a net margin of 10.8%. Revenue grew 6.5% year over year. It earns a return on equity of 3.2%. The balance sheet holds a net cash position of HK$765M. Fundamentals as of Aug 13, 2026

Our scenario range runs from HK$0.6600 (bear case) to HK$1.07 (bull case); at HK$1.40, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 43% below its 52-week high and 8% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -33% fair-value upside, at -39%, 1302 screens richer than that median.

Fair Value models

Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.

Model Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. Evidence
Highest evidence
Growth DCF HK$1.54 HK$2.98 HK$5.16 80
Residual Income HK$0.5900 HK$0.5800 HK$0.5100 76
Rev-Margin DCF HK$0.8000 HK$1.24 HK$1.86 74
All 26 models by family
DCF Models
FCF DCF HK$1.59 HK$2.84 HK$5.89 38
Owner Earnings HK$0.5500 HK$1.05 HK$1.97 31
5Y Revenue Exit HK$0.8000 HK$1.24 HK$1.82 39
5Y EBITDA Exit HK$0.9300 HK$1.52 HK$2.28 41
5Y P/E Exit HK$0.8900 HK$1.45 HK$2.10 38
10Y Revenue Exit HK$1.03 HK$1.57 HK$2.38 36
10Y EBITDA Exit HK$1.13 HK$1.78 HK$2.79 37
10Y P/E Exit HK$1.11 HK$1.72 HK$2.63 35
Earnings-Based
Graham-Dodd HK$0.2300 HK$1.34 HK$1.86 54
Lynch FV HK$0.3800 HK$0.5400 HK$0.7000 50
PEG = 1.0 HK$0.3800 HK$0.5400 HK$0.7000 46
EPV HK$0.2700 HK$0.3000 HK$0.3300 59
Dividend Discount
Gordon GGM HK$0.0400 HK$0.0800 HK$0.1200 70
DDM Multi-Stage HK$0.0400 HK$0.0700 HK$0.0800 61
Multiples
P/E Multiple HK$0.5500 HK$0.7400 HK$0.9200 63
P/S Multiple HK$0.4300 HK$0.5700 HK$0.7100 58
P/B Multiple HK$0.4300 HK$0.5700 HK$0.7100 55
EV/EBIT HK$0.5800 HK$0.7600 HK$0.9400 53
EV/EBITDA HK$0.6600 HK$0.8600 HK$1.06 54
EV/Revenue HK$0.4300 HK$0.5900 HK$0.7600 43
Asset-Based
NCAV (Graham) HK$0.4000 HK$0.5400 HK$0.8000 50
Growth DCF
Growth DCF HK$1.54 HK$2.98 HK$5.16 80
Rev-Margin DCF HK$0.8000 HK$1.24 HK$1.86 74
Economic Profit
Residual Income HK$0.5900 HK$0.5800 HK$0.5100 76
ROIC Compounder HK$0.2700 HK$0.3000 HK$0.3300 72
Growth Earnings
Growth-Adj P/E HK$0.5700 HK$0.8100 HK$1.06 68

Widest divergence: DCF Models (HK$1.52) versus Dividend Discount (HK$0.0700). Highest evidence: Growth DCF (80).

Notify me when 1302 reaches fair value

Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.

Key figures & financial health

Revenue (TTM) HK$1.4B
Revenue growth (YoY) +6.5%
Net margin 10.8%
Return on equity 3.2%
Free cash flow HK$501M FY2025
P/E ratio 34.5 as of Jul 2, 2026
More key figures
Operating margin 23.8%
EPS (TTM) HK$0.0500
EPS growth (YoY) +413%
Net cash HK$765M FY2025

Figures from reported company fundamentals · as of Aug 13, 2026. TTM = trailing twelve months.

Quality Score breakdown

Overall quality 68/100

Of which business quality 69 · Market factors (momentum, volatility) 21

Profitability 32
Margins and returns on capital today
Quality Growth 43
Are margins and returns improving?
Cashflow 98
Earnings quality: real cash, not paper profit
Fin. Strength 89
Balance sheet, leverage, solvency risk
Investment 68
Disciplined investing over empire-building
Low Volatility 53
Calm price path (market factor)
Momentum 10
Price trend over the last 3–12 months (market factor)
52W Momentum 4
Distance to the 52-week high (market factor)
Net Issuance 79
Buybacks instead of dilution

Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.

About the company

LifeTech Scientific Corporation, an investment holding company, develops, manufactures, and trades in interventional medical devices for cardiovascular and peripheral vascular diseases and disorders in Mainland China, Europe, Rest of Asia, India, South America, Africa, and internationally.

Full company description

LifeTech Scientific Corporation, an investment holding company, develops, manufactures, and trades in interventional medical devices for cardiovascular and peripheral vascular diseases and disorders in Mainland China, Europe, Rest of Asia, India, South America, Africa, and internationally. It operates through Structural Heart Diseases Business, Peripheral Vascular Diseases Business, and Cardiac Pacing and Electrophysiology Business segments. It is also involved in biomedical research and development; properties leasing business; and developing, manufacturing, and trading of medical devices, as well as offers technical, consulting, and technology services. LifeTech Scientific Corporation was founded in 1999 and is headquartered in Shenzhen, China.

Company description, as reported by the company or data provider.

Revenue & earnings trend

FY2021 – FY2025 · reported fiscal years

LifeTech Scientific Corp reported revenue of HK$1.4B in FY2025 versus HK$925M in FY2021, a compound +10.3%/yr. Reported net income was HK$148M in FY2025, compounding −15.7%/yr from FY2021.

Growth Quality 95/100
Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Latest Revenue (FY 2025)
HK$1.4B
Latest YoY
+5.1%
Avg. growth/yr (3Y) ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump.
+7.7%
Avg. growth/yr (5Y) ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump.
+16.4%
Avg. growth/yr (16Y) ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump.
+19.5%
Revenue +10.3%/yr
FY21 HK$925M
FY22 HK$1.1B
FY23 HK$1.3B
FY24 HK$1.3B
FY25 HK$1.4B
Net income −15.7%/yr
FY21 HK$292M
FY22 HK$325M
FY23 HK$263M
FY24 HK$222M
FY25 HK$148M
Character of growth · EPS growth decomposed (2015-2025) +11.8 % p.a.
Revenue per share +16.2 pp

of which total revenue +17.6 pp · buybacks/dilution −1.4 pp

EBIT margin −5.3 pp
Tax rate +1.3 pp
Residual (interest, one-offs) −0.3 pp

Absolute contributions in percentage points per year; they sum to the EPS growth rate. Start and end points are 3-year averages (details on hover).

1302 screens 39% overvalued. Compare with Abbott Laboratories, →

Run the numbers yourself: free valuation calculators
DCF CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorFama-French ModelIntrinsic Value
Share or link this analysis
𝕏 Post WhatsApp LinkedIn Reddit
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

LifeTech Scientific Corp · Fair Value
HK$0.8600 −39%Fair Value
Calculator →

Cite: Fair Value Calculator (2026). "LifeTech Scientific Corp Fair Value". https://www.fairvalue-calculator.com/stock/1302

Peer Group

Medical Devices · 350 stocks

How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.

Quality Score 68 · Top 25%
Fair Value upside −39% · Below median
Return on equity (TTM) 3% · Above median
Return on assets 2% · Above median
Net margin (TTM) 11% · Above median
Operating margin (TTM) 24% · Top 25%
Revenue growth 7% · Above median
Dividend yield (TTM) 0.3% · Bottom 25%
Debt / equity 0.16× · Higher than median

Valuation Multiples vs Medical Devices median · lower = cheaper

P/E (TTM) 34.5× · Pricier than median
P/B 1.73× · Pricier than median
P/S (TTM) 4.43× · Pricier than 75% of peers
P/FCF 1.5× · Cheaper than median
EV/EBITDA 20.1× · Pricier than median

Snowflake

Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.

VALUE 0 · sector 0
FUTURE 33 · sector 30
PAST 13 · sector 7
HEALTH 92 · sector 97
DIVIDEND 7 · sector 38

VALUE 0: the price sits above our fair-value range.

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.

Similar stocks

10 more Medical Devices stocks, each showing price versus our Fair Value estimate (as of Aug 13, 2026).

Stock Price Fair Value vs Fair Value
Abbott Laboratories, ABT $110.91 $74.79 -33%
Stryker Corporation SYK $347.21 $186.28 -46%
Medtronic plc MDT $90.76 $65.57 -28%
Boston Scientific Corporation BSX $51.42 $38.44 -25%
Edwards Lifesciences Corporation EW $93.05 $41.02 -56%
Shenzhen Mindray Bio-Medical Electronics Co 300760 ¥153.60 ¥147.63 -4%
Shanghai United Imaging Healthcare Co 688271 ¥110.50 ¥43.60 -61%
Demant A/S DEMANT kr 289.60 kr 161.17 -44%
Getinge AB GETIB kr 239.30 kr 192.14 -20%
Sectra AB SECTB kr 280.00 kr 66.81 -76%

Compare LifeTech Scientific Corp with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Frequently asked questions

Is LifeTech Scientific Corp (1302) overvalued or undervalued?
As of Aug 13, 2026, our model estimates a fair value of HK$0.8600 versus a price of HK$1.40, about −39% (overvalued).
What is the fair value of 1302?
Our model-based fair value for LifeTech Scientific Corp is HK$0.8600 (as of Aug 13, 2026), built from audited fundamentals. The current price is HK$1.40.
What is the quality score of 1302?
LifeTech Scientific Corp has a Quality Score of 68/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the revenue of LifeTech Scientific Corp (1302)?
LifeTech Scientific Corp reported trailing-twelve-month revenue of about HK$1.4B (latest available figure, as of Aug 13, 2026).
What is the net profit margin of 1302?
The net profit margin of LifeTech Scientific Corp is about 10.8%, meaning it keeps roughly 10.8% of revenue as net income. Based on the latest reported figures.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.

14 days Pro free · no card

Track LifeTech Scientific Corp and try Pro for 14 days

One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.

Zero risk: nothing is ever charged. After 14 days you decide whether to stay.